Global Fecal Calprotectin Test Market projected to grow to USD 366.15 million by 2033

From GlobeNewswire: 2024-06-22 02:00:00

The Global Fecal Calprotectin Test Market is projected to grow from USD 126.15 million in 2023 to USD 366.15 million by 2033, with a CAGR of 11.24%. The test measures the level of the protein calprotectin in stool, indicating intestinal inflammation. The test is non-invasive, providing an alternative to endoscopies and colonoscopies, but limited compensation coverage may hinder market growth. The ELISA segment leads the market, offering accurate results with low detection levels. Inflammatory bowel disease (IBD) diagnosis is the dominant indication for fecal calprotectin testing. Hospitals are the primary end-users, offering comprehensive services and specialized expertise. North America holds the largest market share due to advanced healthcare infrastructure and a high incidence of IBD. The market is expected to grow rapidly in the Asia-Pacific region due to increasing gastrointestinal disorders. Key vendors in the market include Bio-Rad Laboratories, Thermo Fisher Scientific, and Meridian Bioscience. In June 2022, R-Biopharm AG announced the acquisition of AusDiagnostics. The Fecal Calprotectin Test market is segmented by assay type, indication, end-user, and region. Browse related reports for market insights and analysis in the healthcare sector.



Read more at GlobeNewswire: Global Fecal Calprotectin Test Market Size To Exceed USD